Ampio Pharmaceuticals (AMPE) Stock Price Up 6.2%

Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) shares rose 6.2% during mid-day trading on Wednesday . The company traded as high as $2.37 and last traded at $2.24. Approximately 620,826 shares were traded during trading, a decline of 41% from the average daily volume of 1,051,843 shares. The stock had previously closed at $2.11.

A number of large investors have recently added to or reduced their stakes in the business. Millennium Management LLC increased its stake in Ampio Pharmaceuticals by 886.6% during the 1st quarter. Millennium Management LLC now owns 782,407 shares of the specialty pharmaceutical company’s stock valued at $2,660,000 after purchasing an additional 703,101 shares in the last quarter. Geode Capital Management LLC increased its stake in Ampio Pharmaceuticals by 101.9% during the 4th quarter. Geode Capital Management LLC now owns 487,410 shares of the specialty pharmaceutical company’s stock valued at $1,983,000 after purchasing an additional 246,040 shares in the last quarter. Carnick & Kubik Group LLC increased its stake in Ampio Pharmaceuticals by 46.2% during the 4th quarter. Carnick & Kubik Group LLC now owns 205,481 shares of the specialty pharmaceutical company’s stock valued at $836,000 after purchasing an additional 64,914 shares in the last quarter. Tibra Equities Europe Ltd bought a new stake in Ampio Pharmaceuticals during the 1st quarter valued at about $585,000. Finally, Cypress Capital Management LLC WY increased its stake in Ampio Pharmaceuticals by 53.5% during the 1st quarter. Cypress Capital Management LLC WY now owns 166,400 shares of the specialty pharmaceutical company’s stock valued at $566,000 after purchasing an additional 58,000 shares in the last quarter.

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply